Josef Vormoor

Research output

Research output per year 1989 1996 2002 2003 2004 2005 2006 2022 2023

• 99 Article
• 9 Review article
• 8 Letter
• 3 Comment/debate
• 3 More
  • 2 Short survey
  • 1 Editorial

Research output per year

Research output per year

Search results

• 2023

  Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement

  Bomken, S., Enshaei, A., Schwalbe, E. C., Mikulasova, A., Dai, Y., Zaka, M., Fung, K. T. M., Bashton, M., Lim, H., Jones, L., Karataraki, N., Winterman, E., Ashby, C., Attarbaschi, A., Bertrand, Y., Bradtke, J., Buldini, B., Burke, G. A. A., Cazzaniga, G., Gohring, G., & 20 othersDe Groot-Kruseman, H. A., Haferlach, C., Nigro, L. L., Parihar, M., Plesa, A., Seaford, E., Sonneveld, E., Strehl, S., Van der Velden, V. H. J., Rand, V., Hunger, S. P., Harrison, C. J., Bacon, C. M., Van Delft, F. W., Loh, M. L., Moppett, J., Vormoor, J., Walker, B. A., Moorman, A. V. & Russell, L. J., Mar 2023, In: Haematologica. 108, 3, p. 717-731 15 p.

  Research output: Contribution to journal › Article › peer-review

  • Burkitt Lymphoma 100%
  • B-Lymphoid Precursor Cells 99%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 81%
  • Immunoglobulins 54%
  • Progression-Free Survival 37%

• Novel Adaption of the SARC-F Score to Classify Pediatric Hemato-Oncology Patients with Functional Sarcopenia

  Verwaaijen, E. J., van der Torre, P., Vormoor, J., Pieters, R., Fiocco, M., Hartman, A. & van den Heuvel-Eibrink, M. M., 3 Jan 2023, In: Cancers. 15, 1

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Sarcopenia 100%
  • Pediatrics 51%
  • Physical Functional Performance 35%
  • Muscle Strength 32%
  • Area Under Curve 13%
• 2022

  Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia

  Tirtakusuma, R., Szoltysek, K., Milne, P., Grinev, V. V., Ptasinska, A., Chin, P. S., Meyer, C., Nakjang, S., Hehir-Kwa, J. Y., Williamson, D., Cauchy, P., Keane, P., Assi, S. A., Ashtiani, M., Kellaway, S. G., Imperato, M. R., Vogiatzi, F., Schweighart, E. K., Lin, S., Wunderlich, M., & 37 othersStutterheim, J., Komkov, A., Zerkalenkova, E., Evans, P., McNeill, H., Elder, A., Martinez-Soria, N., Fordham, S. E., Shi, Y., Russell, L. J., Pal, D., Smith, A., Kingsbury, Z., Becq, J., Eckert, C., Haas, O. A., Carey, P., Bailey, S., Skinner, R., Miakova, N., Collin, M., Bigley, V., Haniffa, M., Marschalek, R., Harrison, C. J., Cargo, C. A., Schewe, D., Olshanskaya, Y., Thirman, M. J., Cockerill, P. N., Mulloy, J. C., Blair, H. J., Vormoor, J., Allan, J. M., Bonifer, C., Heidenreich, O. & Bomken, S., 27 Oct 2022, In: Blood. 140, 17, p. 1875-1890 16 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Deacetylation 100%
  • Regulator Genes 87%
  • Chromatin 74%
  • Epigenomics 74%
  • Mutation 71%
  4 Citations (Scopus)

• Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia

  Dekker, L., Calkoen, F. G., Jiang, Y., Blok, H., Veldkamp, S. R., De Koning, C., Spoon, M., Admiraal, R., Hoogerbrugge, P., Vormoor, B., Vormoor, H. J., Visscher, H., Bierings, M., Van Der Vlugt, M., Van Tinteren, H., Nijstad, A. L., Huitema, A. D. R., Van Der Elst, K. C. M., Pieters, R., Lindemans, C. A., & 1 othersNierkens, S., 12 Apr 2022, In: Blood advances. 6, 7, p. 1969-1976 8 p.

  Research output: Contribution to journal › Article › peer-review

  • CD19 Antigens 100%
  • Chimeric Antigen Receptors 85%
  • fludarabine 81%
  • Cell- and Tissue-Based Therapy 59%
  • Leukemia 51%
  9 Citations (Scopus)

• hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia

  Pal, D., Blair, H., Parker, J., Hockney, S., Beckett, M., Singh, M., Tirtakusuma, R., Nelson, R., McNeill, H., Angel, S. H., Wilson, A., Nizami, S., Nakjang, S., Zhou, P., Schwab, C., Sinclair, P., Russell, L. J., Coxhead, J., Halsey, C., Allan, J. M., & 4 othersHarrison, C. J., Moorman, A. V., Heidenreich, O. & Vormoor, J., 16 Aug 2022, In: Cell Reports Medicine. 3, 8, 100717.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Dexamethasone 100%
  • Induced Pluripotent Stem Cells 88%
  • Leukemia 64%
  • Bone Marrow 57%
  • Resistance 49%
  1 Citation (Scopus)

• Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program ‘iTHER’

  Langenberg, K. P. S., Meister, M. T., Bakhuizen, J. J., Boer, J. M., van Eijkelenburg, N. K. A., Hulleman, E., Ilan, U., Looze, E. J., Dierselhuis, M. P., van der Lugt, J., Breunis, W., Schild, L. G., Ober, K., van Hooff, S. R., Scheijde-Vermeulen, M. A., Hiemcke-Jiwa, L. S., Flucke, U. E., Kranendonk, M. E. G., Wesseling, P., Sonneveld, E., & 34 othersPunt, S., Boltjes, A., van Dijk, F., Verwiel, E. T. P., Volckmann, R., Hehir-Kwa, J. Y., Kester, L. A., Koudijs, M. M. J., Waanders, E., Holstege, F. C. P., Vormoor, H. J., Hoving, E. W., van Noesel, M. M., Pieters, R., Kool, M., Stumpf, M., Blattner-Johnson, M., Balasubramanian, G. P., Van Tilburg, C. M., Jones, B. C., Jones, D. T. W., Witt, O., Pfister, S. M., Jongmans, M. C. J., Kuiper, R. P., de Krijger, R. R., Wijnen, M. H. W., den Boer, M. L., Zwaan, C. M., Kemmeren, P., Koster, J., Tops, B. B. J., Goemans, B. F. & Molenaar, J. J., Nov 2022, In: European Journal of Cancer. 175, p. 311-325 15 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Medical Oncology 100%
  • Pediatrics 54%
  • Child 36%
  • Whole Exome Sequencing 28%
  • Neoplasms 27%

• Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial

  Menne, T., Slade, D., Savage, J., Johnson, S., Irving, J., Kearns, P., Plummer, R., Shenton, G., Veal, G. J., Vormoor, B., Vormoor, J. & Billingham, L., 4 Mar 2022, In: BMJ Open. 12, 3, p. e059872

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • AZD 6244 100%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 59%
  • Dexamethasone 55%
  • Pediatrics 38%
  • T-Lymphoid Precursor Cells 21%
  2 Citations (Scopus)

• Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma

  Brivio, E., Baruchel, A., Beishuizen, A., Bourquin, J. P., Brown, P. A., Cooper, T., Gore, L., Kolb, E. A., Locatelli, F., Maude, S. L., Mussai, F. J., Vormoor-Bürger, B., Vormoor, J., von Stackelberg, A. & Zwaan, C. M., Mar 2022, In: European Journal of Cancer. 164, p. 1-17 17 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Immunotherapy 100%
  • Lymphoma 94%
  • Leukemia 92%
  • Pediatrics 73%
  • Antibodies 62%
  8 Citations (Scopus)
• 2021

  MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance

  van der Zwet, J. C. G., Buijs-Gladdines, J. G. C. A. M., Cordo’, V., Debets, D. O., Smits, W. K., Chen, Z., Dylus, J., Zaman, G. J. R., Altelaar, M., Oshima, K., Bornhauser, B., Bourquin, J. P., Cools, J., Ferrando, A. A., Vormoor, J., Pieters, R., Vormoor, B. & Meijerink, J. P. P., Dec 2021, In: Leukemia. 35, 12, p. 3394-3405 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 100%
  • Drive 78%
  • Steroids 56%
  • Interleukin-7 54%
  • Interleukin-7 Receptors 39%
  13 Citations (Scopus)

• Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia

  Shi, Y., Beckett, M. C., Blair, H. J., Tirtakusuma, R., Nakjang, S., Enshaei, A., Halsey, C., Vormoor, J., Heidenreich, O., Krippner-Heidenreich, A. & van Delft, F. W., 1 Apr 2021, In: Haematologica. 106, 4, p. 1056-1066 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Dasatinib 100%
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 95%
  • Dexamethasone 66%
  • Drug Combinations 45%
  • Glucocorticoid Receptor Deficiency 43%
  16 Citations (Scopus)
• 2020

  COVID-19 - Impact on Childhood Haematology Patients

  Wolfs, T. F. W., Attarbaschi, A., Balduzzi, A., Bernardo, M. E., Bomken, S., Borkhardt, A., Bourquin, J-P., Dufour, C., Gennery, A., Grainger, J., Hasle, H., Hrusak, O., Izraeli, S., Mechinaud, F., Trka, J. & Vormoor, J., Oct 2020, In: HemaSphere. 4, 5, p. e465

  Research output: Contribution to journal › Article › peer-review

  Open Access
• 2019

  Allogeneic hematopoietic cell transplantation in Farber disease

  Ehlert, K., Levade, T., Di Rocco, M., Lanino, E., Albert, M. H., Führer, M., Jarisch, A., Güngör, T., Ayuk, F. & Vormoor, J., Mar 2019, In: Journal of Inherited Metabolic Disease. 42, 2, p. 286-294 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Farber Lipogranulomatosis 100%
  • Cell Transplantation 59%
  • Allogeneic Cells 59%
  • Genetic Association Studies 29%
  • Acid Ceramidase 24%
  6 Citations (Scopus)

• Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM

  Matheson, E. C., Thomas, H., Case, M., Blair, H., Jackson, R. K., Masic, D., Veal, G., Halsey, C., Newell, D. R., Vormoor, J. & Irving, J. A. E., 31 Aug 2019, In: Haematologica. 104, 9, p. 1804-1811 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • AZD 6244 100%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 59%
  • Glucocorticoids 55%
  • Up-Regulation 43%
  • Dexamethasone 37%
  14 Citations (Scopus)
• 2018

  Accelerating drug development in pediatric cancer: A novel Phase i study design of venetoclax in relapsed/refractory malignancies

  Place, A. E., Goldsmith, K., Bourquin, J. P., Loh, M. L., Gore, L., Morgenstern, D. A., Sanzgiri, Y., Hoffman, D., Zhou, Y., Ross, J. A., Prine, B., Shebley, M., McNamee, M., Farazi, T., Kim, S. Y., Verdugo, M., Lash-Fleming, L., Zwaan, C. M. & Vormoor, J., Sept 2018, In: Future oncology (London, England). 14, 21, p. 2115-2129 15 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • Drug Development 59%
  • Pediatrics 40%
  • Neoplasms 20%
  • B-Cell Chronic Lymphocytic Leukemia 16%
  32 Citations (Scopus)

• The MLL recombinome of acute leukemias in 2017

  Meyer, C., Burmeister, T., Gröger, D., Tsaur, G., Fechina, L., Renneville, A., Sutton, R., Venn, N. C., Emerenciano, M., Pombo-De-Oliveira, M. S., Barbieri Blunck, C., Almeida Lopes, B., Zuna, J., Trka, J., Ballerini, P., Lapillonne, H., De Braekeleer, M., Cazzaniga, G., Corral Abascal, L., Van Der Velden, V. H. J., & 51 othersDelabesse, E., Park, T. S., Oh, S. H., Silva, M. L. M., Lund-Aho, T., Juvonen, V., Moore, A. S., Heidenreich, O., Vormoor, J., Zerkalenkova, E., Olshanskaya, Y., Bueno, C., Menendez, P., Teigler-Schlegel, A., Zur Stadt, U., Lentes, J., Göhring, G., Kustanovich, A., Aleinikova, O., Schäfer, B. W., Kubetzko, S., Madsen, H. O., Gruhn, B., Duarte, X., Gameiro, P., Lippert, E., Bidet, A., Cayuela, J. M., Clappier, E., Alonso, C. N., Zwaan, C. M., Van Den Heuvel-Eibrink, M. M., Izraeli, S., Trakhtenbrot, L., Archer, P., Hancock, J., Möricke, A., Alten, J., Schrappe, M., Stanulla, M., Strehl, S., Attarbaschi, A., Dworzak, M., Haas, O. A., Panzer-Grümayer, R., Sedék, L., Szczepa, T., Caye, A., Suarez, L., Cavé, H. & Marschalek, R., 1 Feb 2018, In: Leukemia. 32, 2, p. 273-284 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Leukemia 100%
  • Genes 49%
  • Introns 29%
  • Gene Fusion 17%
  • Residual Neoplasm 16%
  389 Citations (Scopus)
• 2017

  Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia

  Elder, A., Bomken, S., Wilson, I., Blair, H. J., Cockell, S., Ponthan, F., Dormon, K., Pal, D., Heidenreich, O. & Vormoor, J., Dec 2017, In: Leukemia. 31, 12, p. 2577-2586 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 100%
  • Stochastic Processes 25%
  • Transplants 21%
  • Leukemia 13%
  • Stem Cells 12%
  22 Citations (Scopus)

• Early phase clinical trials of anticancer agents in children and adolescents-an ITCC perspective

  Moreno, L., Pearson, A. D. J., Paoletti, X., Jimenez, I., Geoerger, B., Kearns, P. R., Zwaan, C. M., Doz, F., Baruchel, A., Vormoor, J., Casanova, M., Pfister, S. M., Morland, B. & Vassal, G., 1 Aug 2017, In: Nature reviews. Clinical oncology. 14, 8, p. 497-507 11 p.

  Research output: Contribution to journal › Review article › peer-review

  • Investigational Therapies 100%
  • Antineoplastic Agents 78%
  • Drug Development 57%
  • Clinical Trials 52%
  • Child 35%
  51 Citations (Scopus)

• From class waivers to precision medicine in paediatric oncology

  Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium, Jul 2017, In: The Lancet Oncology. 18, 7, p. e394-e404

  Research output: Contribution to journal › Review article › peer-review

  • Precision Medicine 100%
  • Pediatrics 59%
  • Pharmaceutical Preparations 34%
  • Child 17%
  • Neoplasms 13%
  37 Citations (Scopus)
• 2016

  BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance

  Weiland, J., Pal, D., Case, M., Irving, J., Ponthan, F., Koschmieder, S., Heidenreich, O., Von Stackelberg, A., Eckert, C., Vormoor, J. & Elder, A., 1 Sept 2016, In: Leukemia. 30, 9, p. 1920-1923 4 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  17 Citations (Scopus)

• Dormancy Stems the Tide of Chemotherapy

  Pal, D., Heidenreich, O. & Vormoor, J., 12 Dec 2016, In: Cancer Cell. 30, 6, p. 825-826 2 p.

  Research output: Contribution to journal › Short survey › peer-review

  Open Access

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 100%
  • Dissection 87%
  • Phenotype 61%
  • Drug Therapy 59%
  • Neoplasms 32%
  6 Citations (Scopus)

• Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia

  Pal, D., Blair, H. J., Elder, A., Dormon, K., Rennie, K. J., Coleman, D. J. L., Weiland, J., Rankin, K. S., Filby, A., Heidenreich, O. & Vormoor, J., 1 Aug 2016, In: Leukemia. 30, 8, p. 1691-1700 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 100%
  • Leukemia 83%
  • Maintenance 71%
  • In Vitro Techniques 44%
  • Mesenchymal Stem Cells 22%
  32 Citations (Scopus)

• The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts

  Williams, M. T. S., Yousafzai, Y. M., Elder, A., Rehe, K., Bomken, S., Frishman-Levy, L., Tavor, S., Sinclair, P., Dormon, K., Masic, D., Perry, T., Weston, V. J., Kearns, P., Blair, H., Russell, L. J., Heidenreich, O., Irving, J. A. E., Izraeli, S., Vormoor, J., Graham, G. J., & 1 othersHalsey, C., 21 Apr 2016, In: Blood. 127, 16, p. 1998-2006 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 100%
  • Cerebrospinal Fluid 88%
  • Dilution 82%
  • Central Nervous System 75%
  • B-Lymphoid Precursor Cells 35%
  51 Citations (Scopus)
• 2015

  CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia

  Weiland, J., Elder, A., Forster, V., Heidenreich, O., Koschmieder, S. & Vormoor, J., 1 Jul 2015, In: Pediatric Blood and Cancer. 62, 7, p. 1144-1148 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 100%
  • blinatumomab 88%
  • Chimeric Antigen Receptors 68%
  • T-Lymphocytes 63%
  • B-Lymphoid Precursor Cells 61%
  21 Citations (Scopus)

• Errata: Irving J, Matheson E, Minto L, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23):3420-3430

  Irving, J., Matheson, E., Minto, L., Blair, H., Case, M., Halsey, C., Swidenbank, I., Ponthan, F., Kirschner-Schwabe, R., Groeneveld-Krentz, S., Hof, J., Allan, J., Harrison, C., Vormoor, J., Von Stackelberg, A. & Eckert, C., 29 Jan 2015, In: Blood. 125, 5, p. 890 1 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

• The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia

  Eswaran, J., Sinclair, P., Heidenreich, O., Irving, J., Russell, L. J., Hall, A., Calado, D. P., Harrison, C. J. & Vormoor, J., 7 Aug 2015, In: Leukemia. 29, 8, p. 1623-1631 9 p.

  Research output: Contribution to journal › Review article › peer-review

  • Pre-B Cell Receptors 100%
  • B-Lymphoid Precursor Cells 69%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 57%
  • B-Lymphocytes 16%
  • Cell Cycle Checkpoints 7%
  26 Citations (Scopus)
• 2014

  Development of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imaging

  Vormoor, B., Knizia, H. K., Batey, M. A., Almeida, G. S., Wilson, I., Dildey, P., Sharma, A., Blair, H., Hide, I. G., Heidenreich, O., Vormoor, J., Maxwell, R. J. & Bacon, C. M., 7 Jan 2014, In: PLoS ONE. 9, 1, e85128.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Ewing's Sarcoma 100%
  • Bone Diseases 91%
  • Heterografts 73%
  • Bone and Bones 39%
  • Osteosarcoma 34%
  33 Citations (Scopus)

• Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia

  Scherr, M., Elder, A., Battmer, K., Barzan, D., Bomken, S., Ricke-Hoch, M., Schröder, A., Venturini, L., Blair, H. J., Vormoor, J., Ottmann, O., Ganser, A., Pich, A., Hilfiker-Kleiner, D., Heidenreich, O. & Eder, M., Mar 2014, In: Leukemia. 28, 3, p. 554-565 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 100%
  • Apoptosis 41%
  • MicroRNAs 28%
  • Isotope Labeling 24%
  • Pharmacology 22%
  50 Citations (Scopus)

• Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition

  Irving, J., Matheson, E., Minto, L., Blair, H., Case, M., Halsey, C., Swidenbank, I., Ponthan, F., Kirschner-Schwabe, R., Groeneveld-Krentz, S., Hof, J., Allan, J., Harrison, C., Vormoor, J., Von Stackelberg, A. & Eckert, C., 24 Sept 2014, In: Blood. 124, 23, p. 3420-3430 11 p.

  Research output: Contribution to journal › Article › peer-review

  • AZD 6244 100%
  • Mitogen-Activated Protein Kinase Kinases 98%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 89%
  • Selumetinib 87%
  • Mutation 76%
  171 Citations (Scopus)
• 2013

  Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations

  Rehe, K., Wilson, K., Bomken, S., Williamson, D., Irving, J., den Boer, M. L., Stanulla, M., Schrappe, M., Hall, A. G., Heidenreich, O. & Vormoor, J., Jan 2013, In: EMBO molecular medicine. 5, 1, p. 38-51 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 100%
  • Leukemia 83%
  • Population 39%
  • Differentiation Antigens 28%
  • Neoplastic Stem Cells 27%
  61 Citations (Scopus)

• Erratum: Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression (Leukemia (2013) 27 (718-721) DOI: 10.1038/leu.2012.206)

  Bomken, S., Buechler, L., Rehe, K., Ponthan, F., Elder, A., Blair, H., Bacon, C. M., Vormoor, J. & Heidenreich, O., Aug 2013, In: Leukemia. 27, 8, p. 1792 1 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

• Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression

  Bomken, S., Buechler, L., Rehe, K., Ponthan, F., Elder, A., Blair, H., Bacon, C. M., Vormoor, J. & Heidenreich, O., Mar 2013, In: Leukemia. 27, 3, p. 718-721 4 p.

  Research output: Contribution to journal › Letter › peer-review
  23 Citations (Scopus)

• The MLL recombinome of acute leukemias in 2013

  Meyer, C., Hofmann, J., Burmeister, T., Gröger, D., Park, T. S., Emerenciano, M., Pombo De Oliveira, M., Renneville, A., Villarese, P., MacIntyre, E., Cavé, H., Clappier, E., Mass-Malo, K., Zuna, J., Trka, J., De Braekeleer, E., De Braekeleer, M., Oh, S. H., Tsaur, G., Fechina, L., & 67 othersVan Der Velden, V. H. J., Van Dongen, J. J. M., Delabesse, E., Binato, R., Silva, M. L. M., Kustanovich, A., Aleinikova, O., Harris, M. H., Lund-Aho, T., Juvonen, V., Heidenreich, O., Vormoor, J., Choi, W. W. L., Jarosova, M., Kolenova, A., Bueno, C., Menendez, P., Wehner, S., Eckert, C., Talmant, P., Tondeur, S., Lippert, E., Launay, E., Henry, C., Ballerini, P., Lapillone, H., Callanan, M. B., Cayuela, J. M., Herbaux, C., Cazzaniga, G., Kakadiya, P. M., Bohlander, S., Ahlmann, M., Choi, J. R., Gameiro, P., Lee, D. S., Krauter, J., Cornillet-Lefebvre, P., Te Kronnie, G., Schäfer, B. W., Kubetzko, S., Alonso, C. N., Zur Stadt, U., Sutton, R., Venn, N. C., Izraeli, S., Trakhtenbrot, L., Madsen, H. O., Archer, P., Hancock, J., Cerveira, N., Teixeira, M. R., Lo Nigro, L., Möricke, A., Stanulla, M., Schrappe, M., Sedék, L., Szczepański, T., Zwaan, C. M., Coenen, E. A., Van Den Heuvel-Eibrink, M. M., Strehl, S., Dworzak, M., Panzer-Grümayer, R., Dingermann, T., Klingebiel, T. & Marschalek, R., Nov 2013, In: Leukemia. 27, 11, p. 2165-2176 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Biphenotypic Acute Leukemia 100%
  • Leukemia 50%
  • Genes 13%
  • Hospital Distribution Systems 7%
  • Pediatrics 7%
  345 Citations (Scopus)
• 2012

  Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia

  Nicholson, L., Knight, T., Matheson, E., Minto, L., Case, M., Sanichar, M., Bomken, S., Vormoor, J., Hall, A. & Irving, J., Mar 2012, In: Genes Chromosomes and Cancer. 51, 3, p. 250-256 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 100%
  • Exons 85%
  • Lymphoma 84%
  • Ubiquitin-Protein Ligases 77%
  • Mitogen-Activated Protein Kinase Kinases 73%
  14 Citations (Scopus)

• Favorable outcome in infants with AML after intensive first- and second-line treatment: An AML-BFM study group report

  Creutzig, U., Zimmermann, M., Bourquin, J. P., Dworzak, M. N., Kremens, B., Lehrnbecher, T., Von Neuhoff, C., Sander, A., Von Stackelberg, A., Schmid, I., Starý, J., Steinbach, D., Vormoor, J. & Reinhardt, D., Apr 2012, In: Leukemia. 26, 4, p. 654-661 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Acute Myeloid Leukemia 100%
  • Recurrence 30%
  • Survival 29%
  • Survival Rate 26%
  • Cytarabine 19%
  50 Citations (Scopus)

• Leukaemia & cancer in neonates

  Vormoor, J. & Chintagumpala, M., Aug 2012, In: Seminars in Fetal and Neonatal Medicine. 17, 4, p. 183-184 2 p.

  Research output: Contribution to journal › Editorial
  10 Citations (Scopus)

• Stem cells in acute lymphoblastic leukaemia

  Elder, A., Heidenreich, O. & Vormoor, J., Jul 2012, In: European Oncology and Haematology. 8, 3, p. 196-200 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 100%
  • Neoplastic Stem Cells 81%
  • Stem Cells 74%
  • Neoplasms 24%
  • Leukemia 20%

• The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: Results from the AML-BFM 98 study

  Klusmann, J. H., Reinhardt, D., Zimmermann, M., Kremens, B., Vormoor, J., Dworzak, M., Creutzig, U. & Klingebiel, T., 1 Jan 2012, In: Haematologica. 97, 1, p. 21-29 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • ICE protocol 4 100%
  • Allogeneic Cells 49%
  • Stem Cell Transplantation 48%
  • Acute Myeloid Leukemia 44%
  • Siblings 42%
  62 Citations (Scopus)
• 2010

  Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo

  Landmeier, S., Altvater, B., Pscherer, S., Meltzer, J., Sebire, N., Pule, M., Vera, J., Hotfilder, M., Juergens, H., Vormoor, J. & Rossig, C., May 2010, In: Leukemia. 24, 5, p. 1080-1084 5 p.

  Research output: Contribution to journal › Letter › peer-review
  15 Citations (Scopus)

• Flow minimal residual disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34⁺CD38^lowCD19⁺ in B-lineage childhoood acute lymphoblastic leukemia

  Wilson, K., Case, M., Minto, L., Bailey, S., Bown, N., Jesson, J., Lawson, S., Vormoor, J. & Irving, J., Apr 2010, In: Haematologica. 95, 4, p. 679-683 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Residual Neoplasm 100%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 92%
  • Stem Cells 69%
  • Population 29%
  • Phenotype 22%
  22 Citations (Scopus)

• Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT

  Gessner, A., Thomas, M., Garrido Castro, P., Büchler, L., Scholz, A., Brümmendorf, T. H., Martinez Soria, N., Vormoor, J., Greil, J. & Heidenreich, O., Oct 2010, In: Leukemia. 24, 10, p. 1751-1759 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Telomerase 100%
  • Gene Fusion 99%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 34%
  • Acute Myeloid Leukemia 33%
  • Telomere Shortening 23%
  32 Citations (Scopus)

• Understanding the cancer stem cell

  Bomken, S., Fišer, K., Heidenreich, O. & Vormoor, J., 10 Aug 2010, In: British Journal of Cancer. 103, 4, p. 439-445 7 p.

  Research output: Contribution to journal › Short survey › peer-review

  Open Access

  • Neoplastic Stem Cells 100%
  • Stem Cells 69%
  • Cell Biology 54%
  • Clonal Evolution 43%
  • Genetic Phenomena 42%
  169 Citations (Scopus)
• 2009

  A new subgroup of high-risk acute lymphoblastic leukaemia

  Vormoor, J., Feb 2009, In: The Lancet Oncology. 10, 2, p. 101-103 3 p.

  Research output: Contribution to journal › Letter › peer-review

• Epidemiology of leukaemia and lymphoma in children and young adults from the north of England, 1990-2002

  Feltbower, R. G., McNally, R. J. Q., Kinsey, S. E., Lewis, I. J., Picton, S. V., Proctor, S. J., Richards, M., Shenton, G., Skinner, R., Stark, D. P., Vormoor, J., Windebank, K. P. & McKinney, P. A., Feb 2009, In: European Journal of Cancer. 45, 3, p. 420-427 8 p.

  Research output: Contribution to journal › Article › peer-review

  • England 100%
  • Lymphoma 83%
  • Leukemia 82%
  • Young Adult 81%
  • Epidemiology 79%
  21 Citations (Scopus)

• Malignant stem cells in childhood acute lymphoblastic leukemia: the stem cell concept revisited

  Vormoor, H. J., 1 Apr 2009, In: Cell cycle (Georgetown, Tex.). 8, 7, p. 996-9 4 p.

  Research output: Contribution to journal › Article › peer-review

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 100%
  • Stem Cells 74%
  • Heterologous Transplantation 43%
  • Leukemia 27%

• Malignant stem cells in childhood ALL: The debate continues!

  Heidenreich, O. & Vormoor, J., 2009, In: Unknown Journal. 113, 18, p. 4476-4477 2 p.

  Research output: Contribution to journal › Letter › peer-review
  9 Citations (Scopus)
• 2008

  Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice

  Bulk, E., Hascher, A., Liersch, R., Mesters, R. M., Diederichs, S., Sargin, B., Gerke, V., Hotfilder, M., Vormoor, J., Berdel, W. E., Serve, H. & Müller-Tidow, C., 15 Mar 2008, In: Cancer Research. 68, 6, p. 1896-1904 9 p.

  Research output: Contribution to journal › Article › peer-review

  • RNA Interference 100%
  • Non-Small Cell Lung Carcinoma 93%
  • Small Interfering RNA 87%
  • Neoplasm Metastasis 64%
  • Neoplasms 26%
  33 Citations (Scopus)

• In Childhood Acute Lymphoblastic Leukemia, Blasts at Different Stages of Immunophenotypic Maturation Have Stem Cell Properties

  le Viseur, C., Hotfilder, M., Bomken, S., Wilson, K., Röttgers, S., Schrauder, A., Rosemann, A., Irving, J., Stam, R. W., Shultz, L. D., Harbott, J., Jürgens, H., Schrappe, M., Pieters, R. & Vormoor, J., 8 Jul 2008, In: Cancer Cell. 14, 1, p. 47-58 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 100%
  • Stem Cells 74%
  • Inbred NOD Mouse 62%
  • B-Lymphoid Precursor Cells 61%
  • Differentiation Antigens 56%
  219 Citations (Scopus)

• Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia

  Case, M., Matheson, E., Minto, L., Hassan, R., Harrison, C. J., Bown, N., Bailey, S., Vormoor, J., Hall, A. G. & Irving, J. A. E., 15 Aug 2008, In: Cancer Research. 68, 16, p. 6803-6809 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 100%
  • Extracellular Signal-Regulated MAP Kinases 88%
  • Recurrence 58%
  • Mutation 57%
  • Genes 41%
  116 Citations (Scopus)

• Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients

  Allinson, K., Kolve, H., Gumbinger, H. G., Vormoor, J. H., Ehlert, K. & Groll, A. H., Mar 2008, In: Journal of Antimicrobial Chemotherapy. 61, 3, p. 734-742 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hematopoietic Stem Cells 100%
  • Invasive Pulmonary Aspergillosis 96%
  • Pediatrics 64%
  • Voriconazole 56%
  • Leukemia 36%
  53 Citations (Scopus)
• 2007

  Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan

  Hempel, G., Oechtering, D., Lanvers-Kaminsky, C., Klingebiel, T., Vormoor, J., Gruhn, B. & Boos, J., 1 May 2007, In: Journal of Clinical Oncology. 25, 13, p. 1772-1778 7 p.

  Research output: Contribution to journal › Article › peer-review

  • dimethylacetamide 100%
  • Busulfan 73%
  • Pharmacokinetics 42%
  • Child 24%
  • Population 4%
  25 Citations (Scopus)